Authorities in Colombia are investigating allegations that employees at a leading cancer research center were conducting work at their homes, potentially diverting institutional resources to a network of private companies. The investigation, initiated by the Policía Nacional, centers on suspicions that assets belonging to the center were being misappropriated.
The inquiry began following reports of unusual activity involving personnel at the unnamed center, described as a “puntero” – a leading – institution in cancer research. Investigators allege that employees were utilizing their home addresses to carry out tasks typically performed within the center’s facilities. This practice raised concerns about the potential misuse of equipment, data, and other institutional property.
Although the specific nature of the work conducted at private residences remains unclear, authorities suspect a connection to a network of private companies. The investigation aims to determine whether these companies benefited from the alleged diversion of resources, and if so, to what extent. The scale of the potential financial impact is significant, with preliminary estimates suggesting the illicit activity could have generated up to 200 million Colombian pesos (approximately $50,000 USD as of March 23, 2026) per month, according to reports from 2022.
The investigation comes amid broader concerns about pharmaceutical fraud and the adulteration of medications in Latin America. In Ecuador, a recent operation in November 2023 led to the arrest of seventeen individuals and the seizure of 300,000 units of potentially falsified cancer medications, along with 100,000 medical supplies. Similarly, in Colombia, a network was dismantled in 2022 accused of adulterating expensive cancer and HIV medications, altering expiration dates, and violating cold chain protocols. That earlier case involved a citizen who paid seven million pesos for cancer treatment in 2017, only to discover the medication was ineffective, prompting a formal complaint to the Fiscalía.
The current investigation is being led by the Fiscalía, with support from the CTI (Technical Investigation Corps) of the Fiscalía, the Army, and the Policía Nacional. Authorities have conducted nineteen raids on the headquarters of two pharmaceutical distributors, five pharmacies, warehouses, and other properties along the Atlantic coast. These searches yielded over a ton of medications used to treat cancer, HIV-AIDS, hemophilia, diabetes, arthritis, and other costly conditions.
The establishment of a public-private research center focused on cancer in Málaga, Spain, in July 2024, highlights the growing international emphasis on collaborative efforts to combat the disease. However, the Colombian investigation underscores the vulnerabilities within the pharmaceutical and research sectors, and the potential for criminal activity to undermine legitimate efforts.
As of today, authorities have not released the names of the individuals under investigation, nor have they disclosed the identities of the private companies suspected of involvement. The Fiscalía has declined to comment further on the ongoing investigation, citing the need to protect the integrity of the process.
